(retry) AACR (abstracts/presentations): search term by organ - gynecologic cancers: ovarian

Results matching the search 1-100 of 107 Session Search Results
		Late-Breaking Research: Tumor Biology 1  Section 11
		Combination Chemotherapy  Section 15
		Human in Mouse Models  Section 29
		Targeting the Microenvironment  Section 33
		Systems Biology  Section 34
		Biomarkers  Section 20
		Genomic Profiling of Cancers  Section 5
		Late-Breaking Research: Molecular and Cellular Biology 1  Section 10
		Altered Glucose Metabolism in Cancer  Section 2
		Pro-Tumorigenic Microenvironment  Section 32
		Biomarkers for Genitourinary and Gynecological Cancers  Section 21
		Biomarkers for Melanoma and Uncommon Cancers  Section 22
		Mechanisms of Drug Resistance 1  Section 16
		Novel Antitumor Agents  Section 17
		Genes and Function and Risk  Section 36
		Genomic Analysis of Cancers  Section 4
		Functional Genomics and Genomics of Model Systems  Section 3
		Altered Cellular Signaling and Cancer Metabolomics  Section 1
		Antibody-targeted Therapy  Room 265, Morial Convention Center
		Circulating RNAs, Epigenetics, and Novel Non-coding RNAs in Cancer  Section 2
		MicroRNAs as Biomarkers and Therapeutics  Section 6
		Metabolic Reprogramming and Autophagy  Section 4
		Late-Breaking Research: Experimental and Molecular Therapeutics 1  Section 11
		Metastasis-Promoting and -Suppressing Genes  Section 31
		Novel Antitumor Agents and Epigenetics  Section 16
		Late-Breaking Research: Clinical Research 1  Section 12
		Regulators of Epithelial-Mesenchymal Transition and Metastasis  Section 33
		Growth Factor Receptors and Surface Antigens as Therapeutic Targets  Section 15
		Novel Molecular Targets  Section 17
		Drug Delivery 2  Section 20
		Cellular and Molecular Mediators of Metastasis  Section 29
		Race/Ethnicity and Disparities in Diagnosis, Treatment, and Outcomes  Section 36
		Biomarkers and Profiling of Metastasis  Section 28
		Diet, Tobacco, Smoking, and Other Lifestyle Factors in Cancer Epidemiology  Section 35
		Cell-Cell Interaction and Tumor Microenvironment  Section 1
		Oncogenes and Tumor Suppressor Genes and Pathways  Section 9
		Regulation of Anticancer Drug Effects  Section 18
		Immune Modulating Agents and Therapeutic Antibodies  Section 25
		New Drugs, Therapeutic Targets, and Treatment Approaches  Section 18
		Assessment of Gene Regulation in the Malignant Context  Section 3
		Therapeutic Antibodies and Vaccines  Section 27
		Adoptive Cell Therapy, Immune Checkpoints, and Vaccines  Section 21
		Regulation of Chromatin State and Gene Expression  Section 8
		Stemness Properties and Therapeutic Targeting in Solid Tumors  Section 33
		Phase I Clinical Trials 1  Section 13
		Drug Delivery  Section 15
		Late-Breaking Research: Molecular and Cellular Biology 2  Section 10
		MicroRNAs in Metastasis and Cancer  Section 5
		Biomarkers and Other Epidemiologic Factors in Cancer Prognosis  Room 357, Morial Convention Center
		Hypoxia and Oxidative Stress  Section 5
		Cell Cycle Control and Checkpoints  Section 2
		Novel Targets and Pathways  Section 17
		Bioinformatic Tools for Analysis and Mathematical Modeling of Clinical Samples  Section 1
		Innate Immune System, Myeloid Cells, and Tumorigenesis  Section 26
		Stemness Properties of Leukemias and Carcinomas  Section 32
		Circulating Biomarkers 2  Section 22
		Translational and Therapeutic Relevance of Perturbations of Gene Regulation in Malignancy  Section 9
		Phase II/III Clinical Trials in Progress  Section 13
		Mechanisms of Drug Resistance 3  Section 14
		New Mechanisms of Anticancer Drug Action  Section 16
		Immune Checkpoints 2  Section 25
		Monoclonal Antibodies and Antibody-Drug Conjugates  Section 15
		Tumor Angiogenesis: Mediators and Mechanisms  Section 34
		Epidemiology of Cancer Prognosis and Survival  Section 35
		Tumor Angiogenesis: Host Interactions and the Tumor Microenvironment  Section 33
		Late-Breaking Research: Experimental and Molecular Therapeutics 3  Section 11
		DNA Double-Strand Break Repair Defects in Cancer: Therapeutic Strategies and Molecular Basis  Section 3
		Stemness Properties of Breast and Ovarian Cancer  Section 31
		Targeting Protein Kinases, Death Pathways, and the Tumor Microenvironment  Section 19
		Proteomics and Mass Spectrometry  Section 20
		New Cell Lines and 3D Models  Section 35
		Novel Targets  Section 17
		Molecular and Cellular Imaging of Cancer 2  Section 34
		Molecular and Cellular Imaging of Cancer 1  Section 33
		Phase II, III, and Special Population Clinical Trials  Section 13
		Novel Antitumor DNA-Reactive Agents  Section 16
		Cell Death 2  Section 3
		Tumor Suppressor Genes and Pathways  Section 8
		Mechanisms and Applications of Immune-based Therapies  Section 27
		Cell Death Pathways and DNA Repair  Section 14
		Immune Cell Activity  Section 31
		Cell Death 1  Section 2
		Host-Tumor Interactions  Section 29
		Immune Modulation from Non-Immunotherapy: Preclinical  Section 26
		Chemical and Viral Carcinogenesis  Section 28
		Drug Design and Delivery  Room 293, Morial Convention Center
		Oncogenic Cell Signaling: Mechanisms and Translational Insight  Room 354, Morial Convention Center
		HDAC, Methyltransferase Inhibitors, and Novel Anticancer Agents  Section 17
		Novel Chemotherapies  Section 19
		Combination Therapies and Approaches to Sensitizing Cancer Cells to Drugs  Section 15
		Targeted Therapy  Section 20
		Cell Signaling  Section 2
		Late-Breaking Research: Molecular and Cellular Biology 3  Section 10
		Molecular Characterizations of Tumors and Translational Studies  Section 18
		Immune Response Monitoring: Preclinical  Section 23
		Molecular Carcinogenesis  Section 32
		Late-Breaking Research: Tumor Biology 4  Section 11
		Cell Adhesion and Tumor Treatment  Section 28
		Immune Modulation from Non-Immunotherapy and Antibodies: Clinical  Section 26
		Cellular Responses to Anticancer Drugs  Section 14
Select/Clear All	Sessions per Page
1 2   Next >>
Session
Presentations